{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital%2C+Hereditary%2C+and+Neonatal+Diseases+and+Abnormalities&page=5", "query": { "condition": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 10330, "total_pages": 1033, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital%2C+Hereditary%2C+and+Neonatal+Diseases+and+Abnormalities&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital%2C+Hereditary%2C+and+Neonatal+Diseases+and+Abnormalities&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T11:01:04.134Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02378883", "title": "Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Arteriovenous Malformations" ], "interventions": [ { "name": "Apollo™ Onyx™ Delivery Micro Catheter", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic Neurovascular Clinical Affairs", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 112, "start_date": "2015-05-18", "completion_date": "2018-02-20", "has_results": true, "last_update_posted_date": "2019-04-29", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 2, "location_summary": "Englewood, Colorado • Boston, Massachusetts", "locations": [ { "city": "Englewood", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02378883" }, { "nct_id": "NCT00477594", "title": "Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lipid Metabolism, Inborn Errors", "Hypercholesterolemia, Autosomal Dominant", "Hyperlipidemias", "Metabolic Diseases", "Hyperlipoproteinemia Type II", "Metabolism, Inborn Errors", "Genetic Diseases, Inborn", "Infant, Newborn, Diseases", "Metabolic Disorder", "Congenital Abnormalities", "Hypercholesterolemia", "Hyperlipoproteinemias", "Dyslipidemias", "Lipid Metabolism Disorders" ], "interventions": [ { "name": "mipomersen sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kastle Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 21, "start_date": "2007-05", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2016-09-09", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 5, "location_summary": "Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Auburn", "state": "Maine" }, { "city": "Biddeford", "state": "Maine" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477594" }, { "nct_id": "NCT02109822", "title": "Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis", "Lung Infection", "Cystic Fibrosis Pulmonary Exacerbation" ], "interventions": [], "intervention_types": [], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 220, "start_date": "2014-01", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2016-10-26", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109822" }, { "nct_id": "NCT01290822", "title": "Optimized Biventricular Pacing Allograft Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Dilated Cardiomyopathy", "Ischemic Cardiomyopathy" ], "interventions": [ { "name": "BiVP", "type": "DEVICE" }, { "name": "AAI Pacing", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Henry M. Spotnitz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2007-01", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-06", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01290822" }, { "nct_id": "NCT04212351", "title": "Frameshift Peptides of Children With NF1", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neurofibromatosis Type 1" ], "interventions": [ { "name": "Frameshift Array blood sample test", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Day to 30 Years" }, "enrollment_count": 60, "start_date": "2019-04-11", "completion_date": "2022-04-27", "has_results": false, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Dallas, Texas", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04212351" }, { "nct_id": "NCT00004729", "title": "Ketogenic Diet for Child Epilepsy and Seizure Control", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Epilepsy", "Seizures", "Lennox-Gastaut Syndrome" ], "interventions": [ { "name": "Ketogenic diet", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "10 Years", "sex": "ALL", "summary": "1 Year to 10 Years" }, "enrollment_count": null, "start_date": "1997-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-12-22", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004729" }, { "nct_id": "NCT02187029", "title": "Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gout" ], "interventions": [ { "name": "PF-06743649", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 30, "start_date": "2014-07", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-11-11", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 4, "location_summary": "Miami, Florida • South Miami, Florida • Overland Park, Kansas", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "South Miami", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02187029" }, { "nct_id": "NCT07651631", "title": "Rapid Evacuation and Access of Cerebral Hemorrhage Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Intracerebral Hemorrhage" ], "interventions": [], "intervention_types": [], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2500, "start_date": "2026-08-12", "completion_date": "2033-06", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07651631" }, { "nct_id": "NCT03060577", "title": "An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atherosclerotic Cardiovascular Disease", "Symptomatic Atherosclerosis", "Type2 Diabetes", "Familial Hypercholesterolemia" ], "interventions": [ { "name": "Inclisiran", "type": "DRUG" }, { "name": "Evolocumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 382, "start_date": "2017-04-27", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-10-21T11:01:04.134Z", "location_count": 8, "location_summary": "Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03060577" }, { "nct_id": "NCT06451757", "title": "KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mitochondrial Diseases", "Maternally Inherited Diabetes and Deafness (MIDD)", "Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)", "Mitochondrial DNA tRNALeu(UUR) m.3243A